Phase I multiple-ascending dose study with TD 9855 for the treatment of pain
Latest Information Update: 07 Sep 2020
Price :
$35 *
At a glance
- Drugs Ampreloxetine (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 27 Aug 2020 Results of pooled analysis of data from two phase I and two Phase II studies, assessing the pharmacokinetics of once-daily oral ampreloxetine and provide dose recommendations for clinical development, published in the Clinical Pharmacokinetics
- 13 Dec 2012 New trial record